InCarda Therapeutics said today that it raised $42 million in an oversubscribed Series B financing round led by Sofinnova and HealthCap.
Proceeds from the round are slated to support a Phase II trial of the company’s inhaled paroxysmal atrial fibrillation drug, InRhythm.
Get the full story at our sister site, Drug Delivery Business News.
The post InCarda Therapeutics raises $42m for inhaled atrial fibrillation drug appeared first on MassDevice.